Additional features of sampling, such as the presence of an adequate concentration of ctDNA in the plasma specimen and/or the concomitant presence of other detectable mutations, might increase the level of confidence, for example, in that a patient has a KRAS/NRAS-wild-type tumour despite no mutation in these genes being found in ctDNA. Here, KRAS is linked to neoplasm.